Detected ·
Degron Therapeutics
——
Clinical-stage biotech Degron Therapeutics closed a $40M Series A Extension led by LAPAM CAPITAL, bringing total capital raised to $95M. The funding will advance their lead program DEG6498, a first-in-class HuR molecular glue degrader that entered the clinic in late 2025.
- Website
- www.degrontx.com
- linkedin.com/company/degrontx
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-05-22 15:12:32 UTC
- Signal ID
- ab300042-6f85-4424-8fc7-56e241d25555
As the API returns it
{
"id": "ab300042-6f85-4424-8fc7-56e241d25555",
"created_at": "2026-05-22T15:12:32.082775Z",
"company_name": "Degron Therapeutics",
"company_website_url": "www.degrontx.com",
"company_linkedin_url": "https://www.linkedin.com/company/degrontx",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*Clinical-stage biotech Degron Therapeutics closed a $40M Series A Extension led by LAPAM CAPITAL, bringing total capital raised to $95M. The funding will advance their lead program DEG6498, a first-in-class HuR molecular glue degrader that entered the clinic in late 2025.*"
}